Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Gene methylation
Drug
Eligibility
CARCINOGENESIS
Algorithm
Immunosuppressant
Dysbiose
Clinical trial
Intestinal crypts
Tuberculosis
Colorectal cancer Colibactin and lipids
Venous thromboembolism
Colectomy
18 FDG-PET/CT
Inclusion
Kidney diseases
Thérapie ciblée
Gene expression
Méthylation
Consensus
Colon cancer
HIV
MALT
Rituximab plus chlorambucil
Dysbiosis
Colorectal cancer
Epigénétiques
PCR
Microbiote
Monitoring
Microbiota
Inflammatory bowel diseases
T1118 translocation
Surgery
Bacteria
IL23
MORTALITY
IBD
DNA methylation
Ulcerative colitis
Rituximab
Anti-TNF agents
Neoadjuvant chemotherapy
DNA METHYLATION
Colonic epithelial primary cells
Biologics
Disability
Epigenetics
Anti-TNF
Safety
Survival
Maintenance therapy
Stricture
Patients experience
Inflammatory bowel disease
Over 80s
Original Article Clinical
Ustekinumab
Acceptability
Helicobacter pylori
COLON-CANCER
Resistance
Vedolizumab
Parvimonas micra
Small molecules
Bactéries
Inflammatory Bowel Diseases
IL12
Effectiveness
Contraindication
Therapeutics
Methylation
Cell adhesion
Clinical guidelines
MARKER
Genes
Upper gastrointestinal tract
Cost effectiveness
Immune cells
Crohn’s disease
Cancer
Alkylating agents
Inhibitor
Colon
Gènes
Screening
MICROBIOTA
Biomarker
Fecal microbiota
Heart disease risk factors
RISK
Crohn's disease
Eradication
Primary sclerosing cholangitis
Endoscopic treatment
Disease Progression
Patient-reported outcome
Résistance
Tailored therapy
Disease progression
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|